A clear, evidence-based walkthrough of hantavirus prognosis — acute survival, ICU trajectory, ECMO outcomes and long-term sequelae — and how the 2026 MV Hondius cluster is being managed inside this framework.
Hantavirus pulmonary syndrome (HPS) in the Americas has a published all-ages case-fatality rate of approximately 36 percent, which means the overall survival rate is roughly 64 percent. For Andes virus specifically — the strain at the centre of the 2026 MV Hondius cluster — case-fatality rates have historically run between 35 and 50 percent depending on the outbreak setting and the time-to-care distribution. By contrast, the Eurasian hantaviral syndrome HFRS (caused by Hantaan, Seoul, Puumala and Dobrava strains) has a much lower case-fatality rate, generally between 1 and 15 percent depending on strain. The headline numbers conceal real variation by age, comorbidity, time-to-care and access to advanced critical care — and prognosis for an individual patient turns on those modifying factors more than on the headline rate.
The dominant driver of HPS prognosis in the published literature is not age, sex or comorbidity — it is time from symptom onset to ICU-level care. Patients who present early in the prodromal phase or at the start of the cardiopulmonary phase, and who reach a tertiary intensive care unit with mechanical ventilation and ECMO capacity, have published outcomes meaningfully better than the headline case-fatality average. Patients who deteriorate at home or who present late after the cardiopulmonary phase has begun fare worse. This is not a small effect. It is the single most consistent finding in the Argentine, Chilean and US HPS cohort literature.
| Phase | Typical timing | What matters for prognosis |
|---|---|---|
| Prodromal | Days 1–5 after symptom onset | Recognition and triage. Same-day medical evaluation with declared exposure history is the highest-yield intervention available to the patient. |
| Cardiopulmonary | Days 5–10, often abrupt onset | Time-to-cannulation for ECMO if needed; cautious fluid management; tertiary ICU experience with HPS. |
| Convalescent | Weeks to months | Deconditioning is universal; lung function typically returns to or near baseline within 6–12 months in most survivors. |
Extracorporeal membrane oxygenation has shifted the survival curve for severe Andes HPS at high-volume centres. The most-cited Chilean Andes virus cohort (Servicio de Salud Magallanes) reports approximately 60 percent survival on ECMO for patients with severe HPS who would otherwise have died of refractory cardiopulmonary failure. The underlying pathology helps explain why ECMO works as well as it does for this disease: HPS is a short-lived capillary leak that lasts roughly four to seven days; ECMO supports oxygenation and circulation through that window without the lung-injuring high airway pressures of conventional mechanical ventilation at this severity. The strongest predictor of ECMO success is time-to-cannulation, with patients placed on the circuit within 24 hours of cardiopulmonary deterioration faring meaningfully better than those put on the circuit after several days of high-pressure ventilation.
Patients who survive the acute cardiopulmonary phase typically follow a recovery trajectory measured in weeks for the acute hospitalisation and months for the post-discharge reconditioning period. The acute hospital stay is dominated by mechanical ventilation and, in severe cases, ECMO; ICU stays of two to four weeks are common in the published severe-case literature, sometimes longer in ECMO survivors. After discharge, patients commonly report deconditioning, prolonged fatigue and reduced exercise tolerance for weeks to months, broadly consistent with the post-ICU syndrome described for other severe ARDS aetiologies. Structured pulmonary rehabilitation, when accessible, shortens that recovery curve.
The published long-term follow-up literature for HPS survivors is thinner than the acute-care literature but converges on a relatively reassuring picture. Most survivors of severe HPS recover lung function to within or near baseline within six to twelve months, including patients who required ECMO during the acute phase. A minority report persistent reduced exercise tolerance, mild restrictive lung changes on pulmonary function testing, or post-ICU psychological sequelae, but a sustained severe long-term respiratory disability is uncommon in published survivor cohorts. The kidney is not a primary target organ in HPS (it is in HFRS), and long-term renal sequelae are not a typical feature of HPS recovery.
Sin Nombre virus, the dominant North American HPS-causing hantavirus, and Andes virus, the South American strain at the centre of the 2026 MV Hondius cluster, have broadly similar acute case-fatality rates in the published literature. Andes virus is unique because it is the only hantavirus species in which limited human-to-human transmission has been documented under conditions of close prolonged contact. That epidemiological feature does not appear to change the per-case acute severity once infection is established; survival curves for symptomatic Andes virus HPS and symptomatic Sin Nombre virus HPS look similar at large enough sample sizes.
The Eurasian hantaviruses — Hantaan, Seoul, Puumala and Dobrava — cause haemorrhagic fever with renal syndrome rather than the pulmonary syndrome of New World hantaviruses. HFRS has substantially better acute survival overall. Puumala virus, common in Scandinavia, has a case-fatality rate often quoted under 1 percent. Seoul virus is roughly 1–2 percent. Hantaan virus in East Asia is more severe, with case-fatality rates historically between 5 and 15 percent. Dobrava virus in the Balkans is similar. The licensed Korean Hantavax vaccine targets Hantaan and Seoul virus and is not relevant to Andes virus or the Americas.
For the MV Hondius cohort specifically, the prognosis picture as of Day 12 of the WHO 42-day monitoring window reads in three layers. First, the cluster as a whole has been characterised as stabilising by WHO: no new PCR-positive results across receiving countries in the past four days, and the cluster-level case-fatality rate (3 deaths against 12 cases) sits at approximately 25 percent — below the historical Andes virus average. Second, the French passenger at Hôpital Bichat-Claude Bernard in Paris remains the most critically ill member of the cohort and the single most-watched clinical data point. Third, the broader receiving-country cohorts — the 18 American passengers at the UNMC National Quarantine Unit in Omaha, the Madrid cohort at Gómez Ulla, the Calandsteiger 7 crew quarantine, and captain Jan Dobrogowski who has now disembarked symptom-free — remain asymptomatic on standard active-monitoring protocols.
A case-fatality rate is a population statistic, not an individual prognosis. Two patients with the same age, the same strain and the same comorbidity profile can have very different outcomes based on time-to-care, baseline cardiopulmonary reserve, and the experience of the receiving centre. For an individual exposed to hantavirus, the right framing is not the population CFR but the personal action plan: know the prodromal symptoms, present urgently if they appear, name the exposure history at triage, and accept rapid escalation to a tertiary ICU at the first sign of respiratory or haemodynamic deterioration.
→ See the live MV Hondius tracker, 14-day timeline, and all 15 hantavirus news sourcesFor HPS in the Americas the published CDC case-fatality rate is approximately 36 percent across all ages and strains; the overall survival rate is therefore about 64 percent. For Andes virus specifically the published case-fatality rate runs between 35 and 50 percent depending on outbreak setting. These are population averages and do not predict any individual patient's outcome.
The single strongest predictor is time-to-care. Patients who present during the prodromal phase or at the start of the cardiopulmonary phase, and who reach a tertiary intensive care unit with mechanical ventilation and ECMO capacity, have published outcomes meaningfully better than the headline average.
The most-cited Chilean Andes virus cohort reports approximately 60 percent survival on ECMO for severe HPS. The strongest predictor of ECMO success is time-to-cannulation; patients placed on the circuit within 24 hours of cardiopulmonary deterioration fare meaningfully better than those put on later.
The acute hospital stay is commonly two to four weeks in severe published cases, sometimes longer in ECMO survivors. Post-discharge, patients commonly report deconditioning and reduced exercise tolerance for weeks to months. Most survivors recover lung function to within or near baseline within 6–12 months.
Sustained severe long-term respiratory disability is uncommon in published HPS survivor cohorts. A minority of survivors report mild restrictive changes on pulmonary function testing or persistent reduced exercise tolerance, but most regain near-baseline lung function within 6–12 months.
In HPS (New World hantaviruses including Andes virus), the kidney is not a primary target organ and long-term renal sequelae are not a typical feature of recovery. In HFRS (Eurasian hantaviruses), the kidney is the dominant acute target and a small share of survivors retain some long-term renal dysfunction.